MedTrace Logo

Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma

NCT03553589 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2018-12-05

No results posted yet for this study

Summary

Endometrial cancer (EC) is the most frequent gynecological malignancy but there is currently lack of both non-invasive diagnostic tools and novel markers to stratify patients based on their risk of future recurrence. Patient care could be improved by advances in these two aspects.

In the present study, the investigators aim to identify diagnostic serum metabolite and protein biomarker signatures for early detection of cancer in asymptomatic high-risk population and prognostic biomarkers for selection of patients with poor prognosis.

Conditions

Interventions

OTHER

Blood sampling

Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)

Sponsors & Collaborators

  • University of Ljubljana, Faculty of Medicine

    collaborator OTHER

  • Medical University of Lublin

    collaborator OTHER

  • Andrea Romano

    lead OTHER

Principal Investigators

  • Andrea Romano · Maastricht University Medical Centre

  • Tea Lanišnik Rižner, Prof. Dr. · Faculty of Medicine, University of Ljubljana, Slovenia

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • Netherlands
  • Poland
  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553589 on ClinicalTrials.gov